IPP Bureau
Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities
By IPP Bureau - November 15, 2025
The observations are procedural in nature and will be responded to within the stipulated time
Caplin Point Laboratories’ subsidiary acquires land in Mexico
By IPP Bureau - November 15, 2025
The investment in land is Rs. 19.85 crore
Pfizer completes up to $10 billion acquisition of Metsera
By IPP Bureau - November 14, 2025
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg
By IPP Bureau - November 14, 2025
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Lupin achieves S&P Global ESG score of 91
By IPP Bureau - November 14, 2025
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
By IPP Bureau - November 14, 2025
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty
By IPP Bureau - November 14, 2025
Terumo BCT and Santersus partner to advance blood purification therapy for sepsis
By IPP Bureau - November 14, 2025
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Hormone therapy for menopause gets green light from FDA
By IPP Bureau - November 14, 2025
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
By IPP Bureau - November 14, 2025
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis opens radioligand therapy facility in Carlsbad, US
By IPP Bureau - November 14, 2025
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
UK MHRA finds gut microbiome research unreliable across labs
By IPP Bureau - November 14, 2025
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Kaiser Permanente’s study highlights power of genetics in preventing heart disease
By IPP Bureau - November 14, 2025
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
By IPP Bureau - November 14, 2025
Fenebrutinib targets cells in the immune system known as B cells and microglia
LANXESS set to showcase cutting-edge infection control solutions
By IPP Bureau - November 14, 2025
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
